Zai Lab Advances ZL-1310 in Phase 1b/2 Trial for Advanced Solid Tumors
Zai Lab announced an update on its Phase 1b/2 clinical study of ZL-1310, an experimental drug designed to treat advanced solid tumors with limited treatment options.
News & Analysis
Curated news and analysis on clinical trials, drug approvals, and medical research.
Antibody-Based Cancer Therapies Show Promise in Breast Cancer, Imaging, and Lymphoma
New antibody-based approaches demonstrate clinical benefits across multiple cancer types, including improved survival in triple-negative breast cancer, enhanced tumor detection via PET imaging, and activity in relapsed mantle cell lymphoma.
TrumpRx Drug Prices Fall Short of UK Costs for Many Medicines
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Syndax Pharmaceuticals Expands Revuforj Access and Reports Strong Commercial Performance
Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.
Colorectal Cancer: Rising Cases in Young Adults Drive Focus on Screening and New Treatments
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
Eight arrested in Hartford narcotics operation, over 1,000 fentanyl sleeves seized
Multiple people were arrested following a city-wide narcotics enforcement operation in Hartford, Connecticut. Police seized over 1,000 sleeves of fentanyl, crack cocaine, a firearm, and more than $8,000 in cash.
Diakonos Oncology DOC1021 Clears Safety Review, Presents Data at Major Cancer Conferences
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
Exercise and Cardio-Oncology Programs Address Heart and Cognitive Risks in Cancer Treatment
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Study Links Teen Cannabis Use to Doubled Risk of Bipolar and Psychotic Disorders
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Research Funding Under Pressure as US and UK Shift Priorities
Research communities in the US and UK face funding disruptions as governments demand greater alignment with national priorities. UKRI has paused grant programs while early-career researchers advocate for increased NIH funding.
New Technologies Enable Whole-Network Mapping of Human Neural Activity
Researchers have developed advanced platforms to study human neural networks, including 3D bioelectronics for brain organoids and scalable 2D neuron networks that reveal brain-like rhythms and drug responses.
AbbVie Advances Immunology Pipeline with Skyrizi, Rinvoq, and Lutikizumab Data Expected in 2026
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
Measles Cases Rise in U.S. as Health Systems Face Preparedness Challenge
Measles cases are reappearing across the United States, challenging health systems unprepared for a disease declared eliminated in 2000. Clinical leaders must ensure rapid identification, isolation protocols, and vaccination strategies to prevent outbreaks.
PROTAC Technology Advances Toward Phase III Trials in Cancer Treatment
Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.
AI Transforms Oncology Trials; Aethlon Advances Hemopurifier Cancer Study in Australia
Agentic AI models are streamlining oncology clinical trial design and reducing phase II to III failure risk. Separately, Aethlon Medical progresses its Hemopurifier device trial in Australia with strong safety data and accelerated patient recruitment.
FDA Drug Approval Decisions Expected in April 2026
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
CellProthera Prepares Phase III Cardiac Stem Cell Trial, Acquires Delivery Catheter
CellProthera plans to launch a Phase III trial of its ProtheraCytes stem cell therapy for heart failure patients in Q1 2027, enrolling 300-400 patients across 50 sites. The company acquired a transendocardial catheter from Celyad Oncology for €5 million to enable precise delivery of the therapy.
Diacerein Emerges as Adjunctive Therapy for Rheumatoid Arthritis
Diacerein, an anthraquinone derivative, shows promise as a disease-modifying agent in rheumatoid arthritis through its anti-inflammatory and chondroprotective actions, with combination therapy appearing to enhance therapeutic benefits.
Mayo Clinic advances two nanoparticle cancer therapies in separate research programs
Mayo Clinic is pursuing two distinct nanoparticle-based cancer treatments: milk-derived nanoparticles for targeted gene therapy in bile duct cancer, and magnetic nanoparticle hyperthermia for metastatic solid tumors.
FDA Rejects Aldeyra's Reproxalap for Dry Eye Disease, Citing Inconsistent Trial Results
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
Showing 20 articles per page